U.S. Markets closed

Earnings Estimates Moving Higher for Insulet (PODD): Time to Buy?

Zacks Equity Research

Insulet Corporation (PODD) is a medical device company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PODD’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Insulet could be a solid choice for investors.

Current Quarter Estimates for PODD

In the past 30 days, 3 estimates have gone higher for Insulet while 1 has gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 8 cents a share 30 days ago, to a loss of 6 cents today, a significant move.

Current Year Estimates for PODD

Meanwhile, Insulet’s current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to 5 lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 3 cents per share 30 days ago to a loss of 2 cents per share today, a significant move.

Bottom Line

The stock has also started to move higher lately, adding 16.4% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

INSULET CORP (PODD): Free Stock Analysis Report

Zacks Investment Research